
Experts Outline Safety Guidelines for Fully Ablative Lasers
Published in the June 2025 issue of Lasers in Surgery and Medicine , the consensus statement brings together expert recommendations on how to prevent and manage complications related to fully ablative laser resurfacing of the face. The authors emphasize that, while individual practice styles vary, consistent themes emerged — highlighting the importance of patient selection, comprehensive counseling, and detailed pre- and postprocedural care to improve safety and outcomes.
Why This Matters
Fully ablative carbon dioxide and erbium-doped yttrium aluminum garnet lasers remain gold standards for treating photodamaged skin because of their ability to provide deep resurfacing and robust collagen remodeling. But these benefits come at a cost: More extensive skin injury and a higher risk for complications compared with fractional or nonablative lasers, according to the authors.
Arisa Ortiz, MD
Risks include prolonged erythema, infection, pigmentary alterations, and scarring — issues that can be distressing to patients and difficult to manage without a standardized care framework. The consensus authors emphasized that, until now, clinical protocols for the prevention and management of complications have been largely based on anecdotal and variable experience.
Asked to comment on the consensus statement, one of the consensus authors, Arisa Ortiz, MD, dermatologist and director of Laser and Cosmetic Dermatology at UC San Diego Health, San Diego, called the statement 'a landmark in laser dermatology.'
'This consensus is a landmark in laser dermatology, finally providing unified, expert-backed guidance for a procedure that has historically lacked standardization. It gives clinicians a clear, practical roadmap for safe and effective fully ablative resurfacing,' Ortiz said.
Pooja Sodha, MD
Pooja Sodha, MD, associate professor of dermatology at George Washington School of Medicine & Health Sciences and director of the Center for Laser and Cosmetic Dermatology, both in Washington, DC, agreed with this sentiment, emphasizing the document is especially useful in clinical practice. 'This consensus helps to organize the thought process of how to prepare, counsel, and treat patients, almost providing a step-by-step guide of items to consider. This is great for new and old practitioners,' Sodha told Medscape Medical News . She was not an author of the statement.
Key Recommendations
The consensus outlines detailed step-by-step strategies to help clinicians reduce the risk for complications following fully ablative laser resurfacing. These recommendations span the entire patient journey — from pretreatment counseling to postoperative monitoring and management of adverse effects:
Infection prevention. The authors recommend antiviral prophylaxis for all patients undergoing full-face resurfacing, even when treatment is limited to perioral or periocular areas. 'The preferred agent for antiviral prophylaxis is valacyclovir, unless otherwise indicated,' they wrote. The consensus group also noted that oral or topical antibacterial prophylaxis may be appropriate in higher-risk individuals, such as those with diabetes or a history of methicillin-resistant Staphylococcus aureus colonization.
The authors recommend antiviral prophylaxis for all patients undergoing full-face resurfacing, even when treatment is limited to perioral or periocular areas. 'The preferred agent for antiviral prophylaxis is valacyclovir, unless otherwise indicated,' they wrote. The consensus group also noted that oral or topical antibacterial prophylaxis may be appropriate in higher-risk individuals, such as those with diabetes or a history of methicillin-resistant colonization. Postprocedural wound care. The authors emphasized the importance of frequent cleansing with soaks and keeping the skin moist with emollients. 'It is beneficial to apply topical lanolin‐free ointment or other appropriate posttreatment topical product,' the group noted.
The authors emphasized the importance of frequent cleansing with soaks and keeping the skin moist with emollients. 'It is beneficial to apply topical lanolin‐free ointment or other appropriate posttreatment topical product,' the group noted. Early recognition of infection. Patients should be educated to report signs such as increasing pain, drainage, erythema, or fever. 'It is appropriate to promptly evaluate (in person or virtually) patients with signs or symptoms concerning for infection,' the authors wrote.
Patients should be educated to report signs such as increasing pain, drainage, erythema, or fever. 'It is appropriate to promptly evaluate (in person or virtually) patients with signs or symptoms concerning for infection,' the authors wrote. Addressing pigmentary changes. The authors note that pigmentary changes such as hyperpigmentation, a common postprocedural complication, often resolve over 6-12 months, but proactive management may improve outcomes. The panel supports the use of 'topical lightening or bleaching agents' as helpful for treating hyperpigmentation and considers laser-based interventions or oral tranexamic acid in select patients, provided clotting risks are ruled out.
The authors note that pigmentary changes such as hyperpigmentation, a common postprocedural complication, often resolve over 6-12 months, but proactive management may improve outcomes. The panel supports the use of 'topical lightening or bleaching agents' as helpful for treating hyperpigmentation and considers laser-based interventions or oral tranexamic acid in select patients, provided clotting risks are ruled out. Scarring management. The consensus group recommended addressing scarring at the earliest signs. Interventions include intralesional corticosteroids or 5-fluorouracil, vascular lasers, or 'laser-assisted drug delivery of corticosteroid and/or 5‐fluorouracil,' according to the authors.
Challenges and Controversies
While the consensus process produced strong agreement in many areas, some topics remained divisive. Only a subset of proposed adverse events and contraindications reached full consensus. For instance, pretreatment counseling about eruptive keratoacanthomas or milia as possible adverse events did not meet agreement thresholds, according to the authors.
Ortiz noted that disagreement over rare complications reflects the complexity of real-world care. 'While most statements achieved strong agreement, there were important areas — like counseling for rare complications or defining contraindications — where expert opinions diverged,' she explained. 'These gray zones underscore the need for continued discussion and individualized care.'
The risk for vitiligo induction after laser resurfacing is still under debate. While not a formal contraindication, the authors suggest that 'practitioners might consider incorporating family history assessments into pretreatment consultations.'
The panel also noted that while darker Fitzpatrick skin types are not a contraindication to fully ablative laser resurfacing of the face, these patients face higher risks for postinflammatory pigmentary changes. Providers should employ strategies to reduce risk, which include conservative settings, rigorous sun protection, and topical corticosteroids after treatment when appropriate, according to the consensus group.
Sodha emphasized this point as an important area for ongoing refinement: 'I believe this statement is important — 'Darker Fitzpatrick skin types were not considered a contraindication to treatment' — and it highlights that our settings in this population need to be adjusted and these patients need to be counseled on the pigmentary risks, but treatment is still possible,' she explained. 'Building continued comfort here and defining the right parameters is worthy of a little more consideration in future guideline development.'
Sodha also noted that although the recommendations may seem straightforward, successful integration takes practice. 'The steps themselves are not difficult. This is about common sense,' she said. 'These recommendations remind us how important repetition is in integrating these principles so they are second nature.'
Looking Ahead
This expert-driven consensus offers a foundation for safe and consistent care in laser resurfacing but also highlights areas for future research, according to the authors.
Ortiz told Medscape Medical News that future data will be essential to address gaps in evidence. 'There's a pressing need for high-quality studies focused on managing complications like hypopigmentation and scarring, particularly to better understand long-term pigmentary outcomes and optimize treatment safety across diverse populations.'
The study received no specific funding. Several authors disclosed financial relationships with industry, while Ortiz and Podha reported no relevant disclosures.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Times
6 hours ago
- New York Times
Israel Says It Has Paused Some Military Activity in Gaza as Anger Grows Over Hunger
The Israeli military said it had paused military activity in parts of Gaza on Sunday to allow in international aid amid global outrage over the severe hunger faced by Palestinians in the besieged enclave. The decision was a sharp reversal by Israel and followed growing international pressure over the dire conditions in Gaza, where nearly one in three people has not been eating for days on end, according to the United Nations World Food Program. Aid agencies and many countries, including some of Israel's traditional allies, say Israel is responsible for the desperate situation after first blocking and then restricting aid deliveries to Gaza for months. Six Palestinians died of malnutrition-related causes over the past day, including two children, adding to a toll of more than 50 deaths in the past month, according to the Gaza health ministry. Doctors, nurses and medics tasked with caring for Gazans are themselves increasingly struggling to eat, and baby formula is in short supply. Israel has blamed the United Nations and its partners, accusing them of failing to bring hundreds of truckloads of aid through Gaza's border crossings. The United Nations says that while some aid is allowed in, Israel has throw up a maze of bureaucratic obstacles and frequently rejects requests to coordinate deliveries, in addition to other challenges. Israeli officials had also argued for months that Hamas was diverting humanitarian aid. But Israeli military officials later said that they had no proof that Hamas was systematically stealing U.N. relief supplies. Want all of The Times? Subscribe.
Yahoo
21 hours ago
- Yahoo
The Real Reason Hydrogen Fuel Isn't More Popular
In the effort to reduce climate change and eliminate the abundance of fossil fuels, one particular element has been identified as so promising that it could be the future of clean fuels. That element is hydrogen. Earth has a massive supply of hydrogen. It can be burned in the same way we use oil or gas, but instead of polluting the air, it only emits water. So if there is plenty of it and it's so clean, why isn't it more popular? There's no chemical element more abundant than hydrogen in the universe, but it's still difficult to obtain in a pure and ready-to-use form. To use it in the same way we use oil and gas, we must manufacture it. The problem is that the manufacturing process itself usually releases significant climate-warming emissions. There is little point in using clean hydrogen energy if the process to create it negates its benefits. Read more: What's Happening To Earth Right Now Can't Be Explained By Climate Models The Problems With Manufacturing Hydrogen Data from the International Energy Agency (IEA), shows that 96% of hydrogen fuel production around the world uses fossil fuels -- releasing at least nine tons of carbon dioxide (CO₂) per ton of hydrogen, and even up to twelve tons. The various production processes used impact the levels of CO₂ emitted. Most of the hydrogen used today -- including around 95% of projects in the U.S. -- is known as gray hydrogen; made by breaking down natural gas using high heat. While this process does produce hydrogen, it also releases about 12 kilograms of CO₂ for every single kilogram of hydrogen. A cleaner option is blue hydrogen, which uses the same method but adds carbon capture technology to trap some of the emissions. Even then, it still releases three to five kilograms of CO₂ per kilogram of hydrogen. As part of a team researching new ways of creating hydrogen, without direct CO₂ emissions, Professor Graham Hutchings of Cardiff University stated, "Finding sustainable ways of creating the products we need for everyday life and to meet net zero ambitions for the future is a key challenge facing the chemical industry. Hydrogen is widely regarded as one way of achieving these ambitions because it is made from natural gas. However, it is extremely energy intensive and, of course, when created through traditional methods, it produces large amounts of carbon dioxide limiting its environmental benefits." Research Into Cleaner Ways To Produce Hydrogen One potential process which would be safer for our climate, is an option referred to as green hydrogen. This utilizes clean and renewable energy, like wind or solar power, to manufacture the hydrogen. The process can emit one kilogram or less of harmful emissions, which is significantly less than the current processes in place for gray and blue hydrogen. Researching the concept at the Massachusetts Institute of Technology (MIT) Energy Initiative, a key stumbling block is the cost of the electrolyzers that are used to split the hydrogen from water. Furthermore, wind and solar power aren't reliable enough for a continuous manufacturing process. That leaves the options of either stopping production when conditions are not ideal, or having to rely on more traditional methods of producing hydrogen, which is counterintuitive. Principal research scientist at the MIT Energy Initiative, Emre Gençer, explained, "If we get cheaper electrolyzers, you will definitely see more green hydrogen coming online ... The reason we are talking about hydrogen today [is] because there are hard to abate sectors with electrification or other decarbonization options, and that's why we see hydrogen as a solution. But that completely depends on how clean our hydrogen production is." Read the original article on BGR. Solve the daily Crossword
Yahoo
a day ago
- Yahoo
Spike in ADHD medication reports
Authorities are investigating a spike in incidents involving one of Australia's most widely used ADHD medications. Adverse event reports linked to medication Vyvanse have spiked massively this year, and the manufacturer says no changes in the chemical production have been made. 'The Therapeutic Goods Administration (TGA) is currently investigating a potential safety signal associated with Vyvanse, including independent testing of the medicine through the TGA Laboratories,' a spokesperson told NewsWire. 'The investigation is the result of a recent increase in adverse event notifications relating to concerns about the quality, safety, and reduced effectiveness of the drug.' 'There are no compliance signals currently under investigation for the facilities used in the manufacture of this product.' A 'signal' is detection of a pattern which requires further investigation. While not formally a pattern in the TGA's eyes, reports of adverse events such as anxiety, ineffectiveness and insomnia have increased massively this year. There have also been 88 reports of issues with the medicines label, which was flagged by the TGA earlier this year for minor typos; however, one of the typos added an extra 'S' to the word capsule; 'Each capsules contains 60mg lisdexamfetamine dimesilate'. The TGA maintains the Database of Adverse Event Notifications, where people report issues with medications. There have been 320 adverse events linked to Vyvanse in the first half of this year, compared to nine reports in the second half of 2024. Inclusion in the database does not confirm the incident is caused by the medication. Reports of ineffective Vyvanse have hit 150 so far this year, along with 88 reports of anxiety, and 73 reports that the therapeutic response has decreased. Prescriptions of Vyvanse have been steadily increasing for the past few years. More than 958,000 scripts were written by public system health workers in 2022, rising to 1.4 million in 2023, and then 1.8m last year, government data shows. In a statement, supplier Takeda Pharmaceuticals Australia said a change of manufacturing facility in 2024 did not alter the chemical composition of the medicine. 'There have been no changes to the formulation,' a Takeda spokesperson told the ABC. Vyvanse was produced with strict quality controls, in line with Australia's Therapeutics Goods Act, the spokesperson said. The labelling typo did not affect the quality of the medication, they said.